Premium Drug Discovery Services
Our clients are seeking answers in their quest to discover effective treatments for patients. Finding these answers is our mission as a CRO. Our method is to accelerate the drug discovery process with the widest possible range of assays and services but also to maintain an integrated view of the journey to a lead drug candidate. We strive to provide excellent data, delivered in a timely, collaborative manner by outstanding scientists. Who are we? We’re your partner.
Let’s Discover Together.
What people are saying
Meet Us at Our Next Event
Latest News
Reaction Biology Launches Innovative Offering Within Its Kinase Testing Platform and Presents New Data at the American Association for Cancer Research (AACR) Annual Meeting 2024
Reaction Biology (“Reaction” or the “Company”), an industry-leading provider of drug discovery and development services, today announced that it will feature its recently launched HotSpot™ ATP-Max KinomeScreen at the American Association for Cancer Research (AACR) Annual Meeting 2024, held April 7-10, 2024, in San Diego, California.
Reaction Biology to Present Data at AACR 2023 Showcasing Expansive Capabilities in Immuno-Oncology Drug Discovery and Development
~ New Data will be Presented on the Company’s Innovative Assay Technologies, Preclinical Profiling Models and Proprietary Screening Platforms ~
~ Reaction Biology will be at Booth #1527 in the AACR 2023 Exhibit Hall ~
Reaction Biology Selected for Participation in National Chemical Biology Consortium to Support Drug Discovery Utilizing Surface Plasmon Resonance (“SPR”) Technology
Reaction Biology Corporation (“Reaction”), an industry-leading provider of drug discovery services, today announced that it has been selected to participate as a Specialized Center in the Chemical Biology Consortium (CBC), the discovery engine of the National Cancer Institute (NCI) Experimental Therapeutics (NExT) Program, administered through the Frederick National Laboratory for Cancer Research (FNLCR).